



Fig.S5. Effect of selumetinib (AZD6244) on growth of intracranial BT-40 xenografts. Mice were treated with selumetinib (75 mg/kg BID) for 49 consecutive days. **A**, Growth of individual IC tumors determined by Bli (Xenogen IVIS); **B**, mean curves for control and treated tumors (\pm SD); **C**, Kaplan-Meier curves showing probability for survival. Mice were euthanized when their health deteriorated as defined in the IACUC protocol. Mean survival for control mice was 39 days, and for selumetinib treated mice 65 days ($P= 0.0017$).